home / stock / hook / hook news

HOOK News and Press, HOOKIPA Pharma Inc. From 03/13/23

Stock Information
Company Name: HOOKIPA Pharma Inc.
Stock Symbol: HOOK
Market: NASDAQ
Website: hookipapharma.com
Menu
HOOK HOOK Quote HOOK Short HOOK News HOOK Articles HOOK Message Board
Get HOOK Alerts

News, Short Squeeze, Breakout and More Instantly...
HOOK - HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors

NEW YORK and VIENNA, March 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today that Terry Coelho will join its Board of Directors, Audit Commi...
HOOK - HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023

NEW YORK and VIENNA, March 08, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2022 financia...

HOOK - Hookipa Pharma gets $10M milestone payment from Roche

Hookipa Pharma ( NASDAQ: HOOK ) has been awarded a $10M milestone payment under a collaborative R&D deal with Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ). The drug developer is working on HB-700, a novel arenaviral immunotherapy for KRAS-mutated cancers. The milestone paymen...

HOOK - HOOKIPA Achieves $10 Million Milestone Payment in Development of Immunotherapy for KRAS-Mutated Cancers

NEW YORK and VIENNA, Austria, Feb. 13, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it has achieved a $10 million non-dilutive milestone ...
HOOK - HOOKIPA to Present at the SVB Securities Global Biopharma Conference

NEW YORK and VIENNA, Austria, Feb. 07, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate in the virtual SVB Se...

HOOK - HOOKIPA Pharma achieves $5M milestone payment under collaboration with Gilead

HOOKIPA Pharma ( NASDAQ: HOOK ) on Wednesday said it had achieved a $5M milestone payment under its collaboration agreement with Gilead Sciences ( GILD ). Shares of the micro-cap clinical-stage biopharma rose 3.8% to $0.83 in afternoon trade. "HOOKIPA completed and deliver...

HOOK - HOOKIPA Pharma Achieves $5 Million Milestone Payment from Gilead Sciences for Progress in the Development of Hepatitis B Vaccine

NEW YORK and VIENNA, Austria, Jan. 04, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapies based on its proprietary arenavirus platform, today announced that it has achieved a $5 million non-dilutive milestone p...
HOOK - HOOKIPA Pharma Appoints Katia Schlienger, M.D., Ph.D., Chief Medical Officer and Malte Peters, M.D., to Board of Directors

NEW YORK and VIENNA, Austria, Dec. 15, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, announced today the promotion of Katia Schlienger, M.D., Ph.D., to Chie...

HOOK - HOOKIPA to Participate in The JMP Securities Hematology and Oncology Summit

NEW YORK and VIENNA, Austria, Nov. 30, 2022 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that the company will participate virtually in investor...

HOOK - HOOKIPA Pharma GAAP EPS of -$0.25 beats by $0.02, revenue of $2.23M misses by $0.68M

HOOKIPA Pharma press release ( NASDAQ: HOOK ): Q3 GAAP EPS of -$0.25 beats by $0.02 . Revenue of $2.23M (-42.4% Y/Y) misses by $0.68M . For further details see: HOOKIPA Pharma GAAP EPS of -$0.25 beats by $0.02, revenue of $2.23M misses by $0.68M

Previous 10 Next 10